Press Releases

LabStyle Innovations to Demonstrate the Dario Smart Meter at the Upcoming Annual Canada Diabetes Association Conference

Dario market reach continues to broaden with initial penetration into North America

Oct 20, 2014

CAESAREA, Israel, Oct. 20, 2014 /PRNewswire/ -- LabStyle Innovations Corp. (OTCQB:DRIOD), developer of the Dario™ Diabetes Management Solution, today announced that it will exhibiting and demonstrating together with Auto Control Medical Inc. at the 17th Annual Canada Diabetes Association CDA/CSEM Professional Conference and Annual Meetings in Winnipeg, Manitoba at the RBC Convention Center from October 22 to October 25, 2014 (

Dario™ is a cloud-based, diabetes management solution which includes novel software applications combined with the patented, 'all-in-one', pocket-sized Dario™ Smart Meter that interfaces with a user's mobile device. 

At booth 35 the Dario™ smart management solution will be demonstrated to an internationally renowned community of educators, clinicians, and scientists in attendance. The exhibition will allow them a first-hand opportunity to learn how Dario assists in managing diabetes, improves communication and education of patients together with increasing the ability to influence diabetes patient adherence and compliance.

The booth will be jointly attended to by LabStyle Innovations and Auto Control Medical Inc. (ACM). ACM is the exclusive distributor for Dario in Canada and is a Canadian leader in the category of medical devices for home use.

"As a person with diabetes myself, I'm very eager to introduce the Dario™ meter to the Canadian market and proud to have the CDA as the forum for our product launch in Canada," said Mr.  Robert Burgy, Auto Control Medical Inc., President. "The CDA annual meeting is an excellent forum for us to expose diabetes professionals to the Dario smart meter. With Dario, diabetes management is not only about generating accurate blood glucose measurements but also about gathering and providing practical information, analysis and suggestions, to help professionals and their patients make better informed decisions and improve their lifestyle."

"We are enthusiastic about bringing the cutting-edge Dario blood glucose monitoring device to the Canadian market and improving the quality of diabetes healthcare for adults, children and their concerned families," said Mr. Eran Kurman, LabStyle's VP of Global Commercial Strategy.

"I look forward to meeting this esteemed group of Diabetes professionals at the CDA and demonstrate the Dario smart meter as an exceptional motivator for people with Diabetes and an excellent tool for Diabetes professionals to understand their patients and aid in their clinical decision support system."

About LabStyle Innovations Corp.

LabStyle Innovations Corp. (OTCQB:DRIOD) develops and commercializes patented technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle's flagship product is the Dario Diabetes Management Solution.  Dario received CE mark certification in September 2013 and began a world rollout in select countries in December 2013.  LabStyle filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario™ smart meter (Dario Blood Glucose Monitoring System) in December 2013.  LabStyle is pursuing patent applications in multiple areas covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services. For more information: and

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of LabStyle Innovations Corp. (the "Company") related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the results of the Company's commercial and regulatory strategies and plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

© LabStyle Innovations Corp.



Investor Relations

Brenda Zeitlin

LabStyle Innovations

Booke and Company Inc.

1 212 490 9095

1 800 896 9062



To view the original version on PR Newswire, visit: